Document Detail


Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study.
MedLine Citation:
PMID:  19963164     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We undertook a retrospective cohort study comparing infection in solid organ transplant recipients receiving alemtuzumab (n = 726) versus basiliximab (n = 215) or antithymocyte globulin (ATG) (n = 85). Eighty-one percent of patients had kidney transplants. Overall, 33% of patients in the alemtuzumab group (240/724) developed infection compared with 40% (87/215) in the basiliximab group (odds ratio [OR], 0.72; 95% confidence interval [CI], 0.53-0.99; P = .04). The frequency of infection was similar in the alemtuzumab and ATG groups (33% versus 36%, respectively, P = .53). The frequency of fungal infections, most caused by Candida spp., was similar in the alemtuzumab and basiliximab groups (10% versus 9%); disseminated fungal infection occurred in 68% of the patients with fungal infection receiving alemtuzumab and in 30% of the patients with fungal infection receiving basiliximab (OR, 4.76; 95% CI, 1.58-14.28; P = .003). Basiliximab posed a higher risk than alemtuzumab for infection. Disseminated candidal infections were more common in patients receiving alemtuzumab.
Authors:
Nasia Safdar; Jeannina Smith; Valerie Knasinski; Colleen Sherkow; Casey Herrforth; Stuart Knechtle; David Andes
Related Documents :
14750074 - A new era of antifungal therapy.
9785744 - Itraconazole in the treatment of superficial cutaneous and mucosal candida infections.
2183644 - Infection after liver transplantation.
6754414 - Asbestos exposure and aspergillus infection.
16580074 - Osteomyelitis of the ear canal caused by staphylococcus lugdunensis.
19508344 - Europe, the bull and the minotaur: the biological legacy of a neolithic love story.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Diagnostic microbiology and infectious disease     Volume:  66     ISSN:  1879-0070     ISO Abbreviation:  Diagn. Microbiol. Infect. Dis.     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2009-12-07     Completed Date:  2010-03-01     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8305899     Medline TA:  Diagn Microbiol Infect Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  7-15     Citation Subset:  IM    
Affiliation:
Department of Medicine, Section Infectious Diseases, University of Wisconsin, Madison, WI 54792, USA. ns2@medicine.wisc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antibodies, Monoclonal / administration & dosage,  adverse effects*
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm / administration & dosage,  adverse effects*
Antilymphocyte Serum / adverse effects,  therapeutic use
Cohort Studies
Female
Graft Rejection / drug therapy
Humans
Immunocompromised Host / drug effects
Immunoglobulin G / administration & dosage,  adverse effects
Immunosuppressive Agents / adverse effects*,  therapeutic use
Kidney Transplantation / adverse effects*
Male
Middle Aged
Mycoses / etiology,  microbiology
Opportunistic Infections / etiology*,  microbiology,  virology
Recombinant Fusion Proteins / administration & dosage,  adverse effects
Retrospective Studies
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antibodies, Neoplasm; 0/Antilymphocyte Serum; 0/Immunoglobulin G; 0/Immunosuppressive Agents; 0/Recombinant Fusion Proteins; 0/basiliximab; 3A189DH42V/alemtuzumab; CUJ2MVI71Y/daclizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Adequate iodine intake of Slovenian adolescents is primarily attributed to excessive salt intake.
Next Document:  The natural history and pathophysiology of flexible flatfoot.